Phase III Results for Alectinib Compared With Crizotinib in ALK+ Metastatic NSCLC

Alice T. Shaw, MD, PhD, director, thoracic oncology, Massachusetts General Hospital, discusses results of the phase III clinical trial comparing alectinib (Alecensa) versus crizotinib (Xalkori) in first-line treatment for ALK-positive, advanced non–small cell lung cancer.